Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Income towards Parent Company of $3.7 million for Q1 2026, down 57.69% year-over-year from $8.8 million in Q1 2025, and up 106.02% quarter-over-quarter from -$61.9 million in Q4 2025.

Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Income towards Parent Company for 10 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Income towards Parent Company fell 57.69% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at -$53.6 million (down 15.06% YoY), while the FY2025 annual figure was -$66.0 million, down 6.86% from the prior year.
  • Income towards Parent Company advanced to $3.7 million in Q1 2026 per SLGL's latest filing, from -$61.9 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $10.9 million in Q2 2025 and bottomed at -$61.9 million in Q4 2025.
  • Historically, Income towards Parent Company has averaged -$10.5 million across 5 years, with a median of $1.3 million in 2024.
  • Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 4355.22% — and 2025, when it sank 659.42%.
  • Sol-Gel Technologies' Income towards Parent Company stood at -$50.9 million in 2022, then retreated by 4.75% to -$53.3 million in 2023, then declined by 4.82% to -$55.9 million in 2024, then fell by 10.78% to -$61.9 million in 2025, then surged by 106.02% to $3.7 million in 2026.
  • Business Quant data shows SLGL's Income towards Parent Company at $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Sol-Gel Technologies 240.26 Mn 230.12 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.73 Mn
Dec 31, 2025 -61.92 Mn
Sep 30, 2025 -6.29 Mn
Jun 30, 2025 10.85 Mn
Mar 31, 2025 8.81 Mn
Dec 31, 2024 -55.89 Mn
Sep 30, 2024 -828,000.00
Jun 30, 2024 1.31 Mn
Mar 31, 2024 6.34 Mn
Dec 31, 2023 -53.32 Mn
Sep 30, 2023 -5.71 Mn
Jun 30, 2023 5.97 Mn
Mar 31, 2023 10.72 Mn
Dec 31, 2022 -50.90 Mn
Sep 30, 2022 3.41 Mn
Jun 30, 2022 134,000.00
Mar 31, 2022 5.60 Mn
Dec 31, 2021 13.55 Mn
Sep 30, 2021 1.27 Mn
Jun 30, 2021 8.03 Mn